
Orchestra BioMed Holdings, Inc.: updates and filings
Price
$7.00
November 19, 2026Market cap $551M
What Ploutos Investor adds for Orchestra BioMed
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 22% since Nov 10, 2026, when the 10-Q these figures come from was filed ($5.73 then, $7.00 on Nov 19, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
February 2026
January 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Oct 1, 2026Regulation FD disclosure, other material eventsForm8-K
- Sep 8, 2026Regulation FD disclosureForm8-K
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jun 23, 2026Shareholder voteForm8-K
- Jun 23, 2026Shares registered for employeesFormS-8
- Jun 16, 2026Additional annual meeting materialFormDEFA14A
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 29, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Mar 12, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 25, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 13, 2026Officer or director changeForm8-K
- Feb 6, 2026Shares registered for employeesFormS-8
- Feb 6, 2026Shares registered for employeesFormS-8
- Jan 12, 2026Other material eventsForm8-K
- Nov 19, 2025Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 14, 2025Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 13, 2025Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Oct 1, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Sep 8, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jun 23, 2026 | 8-K | Shareholder vote | Document |
| Jun 23, 2026 | S-8 | Shares registered for employees | Document |
| Jun 16, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 29, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 12, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 25, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 13, 2026 | 8-K | Officer or director change | Document |
| Feb 6, 2026 | S-8 | Shares registered for employees | Document |
| Feb 6, 2026 | S-8 | Shares registered for employees | Document |
| Jan 12, 2026 | 8-K | Other material events | Document |
| Nov 19, 2025 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 14, 2025 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 13, 2025 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 22, 2020.
The full analysis
What do Orchestra BioMed's filings show?
The filings are where every one of Orchestra BioMed's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.